- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05209165
Semaglutide to Reduce Atrial Fibrillation Burden
October 24, 2022 updated by: Adam Oesterle, San Francisco Veterans Affairs Medical Center
Semaglutide as Treatment of Overweight and Obese Individuals to Reduce Atrial Fibrillation Burden
Atrial fibrillation (AF) is the most common arrhythmia worldwide.
AF is associated with obesity and the co-morbidities of obesity, including hypertension and obstructive sleep apnea (OSA) which increase left atrial (LA) size and decrease LA function.
Semaglutide, a Glucagon-like peptide receptor 1 agonist (GLP-1 RA), is currently approved by the Food and Drug Administration for weight loss for individuals with and without diabetes.
The effects of pharmacologic weight loss with Semaglutide on AF are unknown.
The investigators plan on conducting a randomized controlled trial of semaglutide versus placebo in individuals with paroxysmal or early persistent AF (>10% AF burden on ambulatory monitoring, a previous electrical cardioversion, or AF lasting ≥ 7 days but < 3 months who have a body mass index ≥ 27.0 kg/m2.
The trial will last for 52 weeks.
The primary outcome will be the change in AF burden for 2 weeks, immediately before starting the medication or placebo to two weeks starting at week 50, as determined by an implantable loop recorder or two week ambulatory Additional outcomes will be change in epicardial adipose tissue as determined by chest/abdomen/pelvis computed tomography scan at enrollment and at week 52, change in apnea-hypopnea index from baseline sleep study to week 52 sleep study, change in LA longitudinal strain from baseline echocardiogram to echocardiogram at 52 weeks, and change on symptom surveys.
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
132
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- Veterans Affairs Medical Center San Francisco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients ≥ 18 years old with a BMI ≥ 27 kg/m2 who have paroxysmal AF with a ≥ 10% burden on ambulatory monitoring or a previous electrical cardioversion or early persistent AF (≥ 7 days, < 3 months) who are willing to attempt rhythm control.
Exclusion Criteria:
- Unable to consent
- A personal or family history of medullary thyroid carcinoma
- A personal or family history of multiple endocrine neoplasia syndrome type 2
- History of allergic reaction to Semaglutide or any of its components
- Currently pregnant or planning to become pregnant
- Currently breastfeeding
- History of acute pancreatitis
- History of pancreatic adenocarcinoma
- Previous or current GLP-1 RA use
- Previous or current use of alternative pharmacologic weight loss agents (phentermine, diethylpropion, orlistat, phentermine-topiramate, bupropion- naltrexone, gelesis100, or setmelanotide)
- Unable to tolerate anticoagulation
- History of bariatric surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Matching placebo and intake visit for VA MOVE
|
Experimental: Semaglutide
|
weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Atrial fibrillation burden
Time Frame: 52 weeks
|
Change in AF burden from the two weeks before starting Semaglutide or placebo to the last two weeks of therapy (starting at week 50).
AF burden will be assessed as percent of time in AF for two weeks on an implantable loop recorder.
If the patient declines implantable loop recorder placement, an ambulatory 2-week monitor will be used instead.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epicardial adipose tissue
Time Frame: 52 weeks
|
Change in epicardial adipose tissue on non-contrast chest/abdomen CT scans from baseline and week 52
|
52 weeks
|
Sleep apnea
Time Frame: 52 weeks
|
Change in apnea-hypopnea index from baseline sleep study to sleep study at week 52
|
52 weeks
|
Left atrial function
Time Frame: 52 weeks
|
The change in LA longitudinal strain from the baseline echocardiogram to the echocardiogram at 52 weeks.
|
52 weeks
|
Weight change
Time Frame: 52 weeks
|
From baseline to week 52
|
52 weeks
|
Adherence and Adverse Events
Time Frame: 52 weeks
|
From baseline to week 52
|
52 weeks
|
Participation in VA MOVE
Time Frame: 52 weeks
|
assess participation
|
52 weeks
|
Change in AF burden for four weeks
Time Frame: 52 weeks
|
Change in AF burden for 4 weeks before starting the medication to weeks 48-52.
|
52 weeks
|
Fat depots
Time Frame: 52 weeks
|
change in pericardial, abdominal (visceral and subcutaneous) and hepatic adipose tissue
|
52 weeks
|
Left atrial size and function
Time Frame: 52 weeks
|
Changes in LA size and function between baseline and week 52 echocardiograms: LA volume as assessed using the biplane disk summation method, LA reservoir strain, LA conduit strain, and LA booster pump strain will be assessed as secondary outcomes
|
52 weeks
|
Quality of life on Healthcare Quality of Life surverys
Time Frame: 52 weeks
|
Quality of life on the Short-Form 36 survey and the AF symptoms and severity checklist, which will be completed at baseline and at week 52
|
52 weeks
|
Change in C-reactive Protein (CRP)
Time Frame: 52 weeks
|
Change in the biomarker CRP between baseline and week 52
|
52 weeks
|
Blood pressure
Time Frame: 52 weeks
|
Changes in blood pressure and blood pressure medication use between baseline and week 52 will be assessed at those visits.
|
52 weeks
|
Change in Interleukin-6 (IL-6)
Time Frame: 52 weeks
|
Change in the biomarker IL- 6 between baseline and week 52
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2023
Primary Completion (Anticipated)
May 1, 2027
Study Completion (Anticipated)
May 1, 2028
Study Registration Dates
First Submitted
January 14, 2022
First Submitted That Met QC Criteria
January 14, 2022
First Posted (Actual)
January 26, 2022
Study Record Updates
Last Update Posted (Actual)
October 27, 2022
Last Update Submitted That Met QC Criteria
October 24, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SFVAEP1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary
-
Novo Nordisk A/SCompletedObesity | OverweightJapan, Korea, Republic of
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisorderUnited States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico